UCB PHARMA SA
๐ง๐ชBelgium
- Country
- ๐ง๐ชBelgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2015-08-11
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 249
- Registration Number
- NCT01646268
- Locations
- ๐จ๐ณ
025, Beijing, China
๐จ๐ณ016, Tianjin, China
๐จ๐ณ021, Fuzhou, China
An Open-label, Bioequivalence Study to Evaluate LEV Administered as a 45-min Intravenous Infusion and Same Dosage LEV Oral Tablet in Chinese
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2012-08-03
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 24
- Registration Number
- NCT01618903
- Locations
- ๐จ๐ณ
1, Shanghai, China
A Randomized, Double-blind, Pharmacokinetics Study to Assess Safety, Tolerability of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of Bid Dosing in Chinese Healthy Volunteers
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2012-08-03
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 24
- Registration Number
- NCT01618877
- Locations
- ๐จ๐ณ
1, Shanghai, China
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)
Terminated
- Conditions
- First Posted Date
- 2012-04-13
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 199
- Registration Number
- NCT01577264
- Locations
- ๐ท๐บ
41, Samara, Russian Federation
๐ท๐บ15, Samara, Russian Federation
๐ท๐บ37, Ufa, Russian Federation
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
- First Posted Date
- 2012-04-03
- Last Posted Date
- 2014-08-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 150
- Registration Number
- NCT01569464
- Locations
- ๐บ๐ธ
012, Macon, Georgia, United States
๐บ๐ธ015, St. Louis, Missouri, United States
๐บ๐ธ019, Kalamazoo, Michigan, United States
Bioequivalence Study of Rotigotine Transdermal Patch With Two Different Formulations in Healthy Japanese Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 55
- Registration Number
- NCT01565018
- Locations
- ๐ฉ๐ช
1, Neuss, Germany
Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction
- First Posted Date
- 2012-02-20
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 25
- Registration Number
- NCT01536015
- Locations
- ๐บ๐ธ
014, Houston, Texas, United States
๐บ๐ธ032, Annapolis, Maryland, United States
๐บ๐ธ016, Commack, New York, United States
Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects
- First Posted Date
- 2012-02-16
- Last Posted Date
- 2016-05-06
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 17
- Registration Number
- NCT01534403
- Locations
- ๐ฏ๐ต
11, Fukuoka, Japan
๐ฏ๐ต10, Fukuoka, Japan
๐ฏ๐ต9, Fukuoka, Japan
Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-02-09
- Last Posted Date
- 2014-01-24
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 60
- Registration Number
- NCT01530022
- Locations
- ๐บ๐ธ
002, Overland Park, Kansas, United States
๐บ๐ธ001, Atlanta, Georgia, United States
A Multicenter, Open-label Study to Determine the Effects of Lacosamide on Sleep in Healthy Subjects
- First Posted Date
- 2012-02-09
- Last Posted Date
- 2012-08-20
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 25
- Registration Number
- NCT01530386
- Locations
- ๐บ๐ธ
003, Cleveland, Ohio, United States
๐บ๐ธ005, Little Rock, Arkansas, United States
๐บ๐ธ004, Austin, Texas, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath